CV6-1271 is a first-in-class, specific, oral small molecule inhibitor of dUTPase in preclinical development, designed to improve outcomes for patients with inflammatory diseases such as rheumatoid arthritis. These conditions are driven by overactive or misdirected immune cells that mistakenly attack the body’s own tissues, leading to chronic inflammation, joint pain, swelling, stiffness, and long-term tissue damage.
Current treatments can help manage symptoms, but many patients do not respond fully or experience diminishing benefit over time. CV6 Therapeutics is developing CV6-1271 to work alongside existing cornerstone therapies such as methotrexate, offering a smarter approach to controlling the underlying immune dysfunction — not just relieving symptoms but helping to change the course of disease.
By targeting the abnormal behavior of immune cells at its source, CV6-1271 aims to reduce inflammation more effectively, protect healthy tissues, and improve quality of life for patients living with chronic autoimmune and inflammatory conditions.
